Press releases

31 August, 2015

Regulatory

NeuroVive refocuses CicloMulsion development – discontinues acute myocardial infarction indication

CicloMulsion® development to continue in acute kidney injury and increased focus on development of other drug candidates. Shareholder information meeting to be held on 10th September 2015 in Lund, Swe ...

1 June, 2015

Regulatory

NeuroVive reports topline results of phase III CIRCUS study in acute myocardial infarction

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, reports that the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart attack known as ST-segment el ...

26 May, 2015

Regulatory

NeuroVive Asia signs collaboration agreement with Sanofi for the development and commercialization of CicloMulsion® in South Korea

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that NeuroVive Pharmaceutical Asia group has signed a collaboration agreement with Sanofi's local affiliate for the de ...

26 May, 2015

Regulatory

Sale of shares off the market following share exchange program

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that one of its insider registered persons has executed a limited share sale following completed share swaps from Maas ...

25 May, 2015

Regulatory

Topline result of Phase III study of CicloMulsion® in acute myocardial infarction expected this quarter

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, expects to announce the topline result of the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart ...

7 May, 2015

Regulatory

Published data indicates protective effect of cyclosporine in patients with stroke

The results of a clinical phase II study indicating that cyclosporine counteracts brain injury in a subset of stroke patients undergoing thrombolysis has been published in an article co-authored by on ...

27 April, 2015

Regulatory

First patient enrolled in clinical phase II study for kidney protection during heart surgery

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the first patient has been enrolled in a clinical phase II study for acute kidney injury using the company's prod ...

21 April, 2015

Regulatory

Clinical Phase II study with NeuroSTAT® for traumatic brain injury passes safety evaluation

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the independent safety committee has endorsed moving on to the next dose level without any safety issues, followi ...

20 April, 2015

Regulatory

NeuroVive establishes subsidiary in Lyon and extends collaboration with HCL

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has established a subsidiary in Lyon, France. The establishment is part of a process of extending its ongoing collaboration with ...

17 April, 2015

Regulatory

Development of NVP014 for the treatment of stroke enters new phase in collaboration with Isomerase Therapeutics

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's development project NVP014 for the treatment of ischemic stroke is entering a new phase in coll ...

30 March, 2015

Regulatory

NeuroVive Pharmaceutical AB (publ): report from AGM

NeuroVive Pharmaceutical AB (publ) held its Annual General Meeting (AGM) yesterday, 30 March 2015. A summary of the resolutions follows. All resolutions were passed with the required majority.

25 February, 2015

Regulatory

Notice of Annual General Meeting of NeuroVive Pharmaceutical AB (publ)

The shareholders of NeuroVive Pharmaceutical AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 4 p.m. on Monday, 30 March 2015 at Medicon Vil ...